138 related articles for article (PubMed ID: 27155764)
1. Cell-Penetrating Peptide Penetratin as a Potential Tool for Developing Effective Nasal Vaccination Systems.
Muto K; Kamei N; Yoshida M; Takayama K; Takeda-Morishita M
J Pharm Sci; 2016 Jun; 105(6):2014-2017. PubMed ID: 27155764
[TBL] [Abstract][Full Text] [Related]
2. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
[TBL] [Abstract][Full Text] [Related]
3. Potential of Translationally Controlled Tumor Protein-Derived Protein Transduction Domains as Antigen Carriers for Nasal Vaccine Delivery.
Bae HD; Lee J; Jin XH; Lee K
Mol Pharm; 2016 Sep; 13(9):3196-205. PubMed ID: 27454469
[TBL] [Abstract][Full Text] [Related]
4. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable Hyaluronic Acid Modified with Tetraglycine-l-octaarginine as a Safe Adjuvant for Mucosal Vaccination.
Ukawa M; Tanishita S; Yagi H; Yoshida Y; Tomono T; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Mol Pharm; 2019 Mar; 16(3):1105-1118. PubMed ID: 30715891
[TBL] [Abstract][Full Text] [Related]
6. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
Kamei N; Takeda-Morishita M
J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
[TBL] [Abstract][Full Text] [Related]
7. Efficiency of cell-penetrating peptides on the nasal and intestinal absorption of therapeutic peptides and proteins.
Khafagy el-S; Morishita M; Kamei N; Eda Y; Ikeno Y; Takayama K
Int J Pharm; 2009 Oct; 381(1):49-55. PubMed ID: 19646515
[TBL] [Abstract][Full Text] [Related]
8. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats.
Khafagy el-S; Kamei N; Nielsen EJ; Nishio R; Takeda-Morishita M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):736-43. PubMed ID: 24060698
[TBL] [Abstract][Full Text] [Related]
9. [Nose-to-Brain Delivery of Peptide Drugs Enhanced by Coadministration of Cell-penetrating Peptides: Therapeutic Potential for Dementia].
Kamei N
Yakugaku Zasshi; 2017; 137(10):1247-1253. PubMed ID: 28966266
[TBL] [Abstract][Full Text] [Related]
10. Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms.
Ukawa M; Endo R; Yagi H; Tomono T; Miyata K; Shigeno K; Tobita E; Uto T; Baba M; Sakuma S
Int J Pharm; 2022 Feb; 613():121376. PubMed ID: 34915143
[TBL] [Abstract][Full Text] [Related]
11. Mucosal vaccination using claudin-4-targeting.
Kakutani H; Kondoh M; Fukasaka M; Suzuki H; Hamakubo T; Yagi K
Biomaterials; 2010 Jul; 31(20):5463-71. PubMed ID: 20398936
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
Kamei N; Nielsen EJ; Khafagy el-S; Takeda-Morishita M
Ther Deliv; 2013 Mar; 4(3):315-26. PubMed ID: 23442079
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys.
Torikai Y; Sasaki Y; Sasaki K; Kyuno A; Haruta S; Tanimoto A
J Pharm Sci; 2021 May; 110(5):2038-2046. PubMed ID: 33278410
[TBL] [Abstract][Full Text] [Related]
14. Cell Penetrating Peptide-Based Redox-Sensitive Vaccine Delivery System for Subcutaneous Vaccination.
Wang K; Yang Y; Xue W; Liu Z
Mol Pharm; 2018 Mar; 15(3):975-984. PubMed ID: 29359945
[TBL] [Abstract][Full Text] [Related]
15. Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice.
Kim H; Kimoto T; Sakai S; Takahashi E; Kido H
PLoS One; 2018; 13(1):e0191133. PubMed ID: 29370185
[TBL] [Abstract][Full Text] [Related]
16. Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses.
Kong Q; Kitaoka M; Tahara Y; Wakabayashi R; Kamiya N; Goto M
Int J Pharm; 2019 Dec; 572():118777. PubMed ID: 31678377
[TBL] [Abstract][Full Text] [Related]
17. Mucosal immunity of nasopharynx: an experimental study in TCR-transgenic (OVA23-3) mice.
Yamada T; Kataoka S; Ogasawara K; Ishimitsu R; Hashigucci K; Suzuki T; Kawauchi H
Rhinology; 2005 Sep; 43(3):190-8. PubMed ID: 16218512
[TBL] [Abstract][Full Text] [Related]
18. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
[TBL] [Abstract][Full Text] [Related]
19. Intranasal formulations: promising strategy to deliver vaccines.
Riese P; Sakthivel P; Trittel S; Guzmán CA
Expert Opin Drug Deliv; 2014 Oct; 11(10):1619-34. PubMed ID: 24962722
[TBL] [Abstract][Full Text] [Related]
20. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.
Xu H; Ruwona TB; Thakkar SG; Chen Y; Zeng M; Cui Z
Hum Vaccin Immunother; 2017 Nov; 13(11):2688-2694. PubMed ID: 28933668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
